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To understand the relationship between putative neurohormonal factors operative in hypertension and coronary artery
calciﬁcation(CAC),therelevantcellularactionsofangiotensin(AngII)andendothelin-1(ET-1)arereviewed. There iscompelling
evidence to implicate ET-1 in CAC. ET-1 increases phosphate transport with a 42 to 73% increase in Vmax. Increased cellular
phosphate may induce CAC through increased Ca x phosphate product, transformation of vascular smooth muscle cells into a
bone-producing phenotype or cell apoptosis that releases procalciﬁc substances. ET-1 is increased in several models of vascular
calciﬁcation. ET-1 inhibits inhibitors of calciﬁcation, matrix Gla and osteoprotegerin, while enhancing pro-calciﬁc factors such as
BMP-2 and osteopontin. In contrast, Ang II inhibits phosphate transport decreasing Vmax by 38% and increases matrix Gla. Ang
II also stimulates bone resorption. Vascular calciﬁcation is reduced by ET-1 A receptor antagonists and to a greater extent than
angiotensin receptor blockade although both agents reduce blood pressure.
1.Introduction
The presence and severity of coronary artery calciﬁcation
(CAC) is a predictor of an increased probability of serious
clinicalcardiac eventsincludingdeath [1–4]. Chronic kidney
disease is associated with increased CAC, and in general
the more advanced the stage of kidney disease, the greater
is the amount of CAC [5–9]. The possible causal linkage
between end-stage kidney diseases producing CAC that in
turn accelerates coronary atherosclerotic events has focused
attention on the pathophysiology of CAC in end stage renal
disease with the objective of determining steps in the process
that might be amenable to a suitable intervention to reduce
the high mortality seen in patient with chronic kidney
disease.
While the precise mechanisms producing vascular cal-
ciﬁcation are still being elucidated, investigators contend
that the processes likely involve calcium and phosphorus
metabolic dysfunction, changes of vascular cells, especially
vascular smooth cells (VSMC), into an osteoblastic pheno-
type and an imbalance between procalciﬁcation and anti-
calciﬁcation factors [10]. Vascular calciﬁcation in chronic
kidneydisease vesselsisalsostronglyassociated withvascular
smooth muscle cell death resulting from calcium- and
phosphate-induced apoptosis [11, 12]. Vascular calciﬁcation
induced in aortas cultured in a high phosphate medium
occurs concomitantly with cell death of VSMC via apoptosis
[13]. Inhibition of apoptosis with a general caspase inhibitor
reduces calciﬁcation [13]. Calciﬁcation can be initiated by
the release of membrane-bound matrix vesicles from living
VSMC and also by the release of apoptotic bodies from
dying cells [12]. Vesicles released by VSMC after prolonged
exposure to calcium and phosphate not only accelerate
vascular calciﬁcation but also contain preformed calcium
phosphate complexes [12].
Hypertension is an important risk factor for CAC [14].
Indeed, some data suggest that the presence of hypertension
is the most important determinant of CAC in patients with
chronic kidney disease (CKD). The association between
lower eGFR and higher prevalence of CAC in the Framing-
ham study was attenuated and of less statistical signiﬁcance
after multivariable adjustment for risk factors including2 International Journal of Nephrology
hypertension [5]. Amongst the 6749 participants of the
Multiethnic Study of Atherosclerosis, hypertension was a
major factor accounting for the association of decrements of
kidney function and CAC after adjustment for age, gender,
and race/ethnicity [15]. In a multivariate analysis of patients
with CKD, after considering many factors, the severity of
hypertension, reﬂected by the number of antihypertensive
drugs taken to control hypertension, was signiﬁcantly asso-
ciated with CAC with an odds ratio of 2.4 compared to
patient’s age that had an odds ratio of 1.1 [16].
Hypertension is produced by a wide variety of factors
operating in diﬀerent organs. Two factors that have been
implicated in the pathogenesis of hypertension are the
angiotensin and Endothelin family of peptides. Angiotensin
II is a powerful vasoconstrictor peptide. Endothelin, an
even more potent vasoconstrictor peptide, is released from
endothelial as well as other cell types. This paper examines
the eﬀect of angiotensin II (Ang II) and Endothelin 1 (ET-1)
on vascular calciﬁcation focusing on diﬀerences in putative
pathways leading to vascular calciﬁcation. Despite similar
eﬀects on blood pressure, these two peptides produce diﬀer-
ent eﬀects on the process of calciﬁcation. These diﬀerences
are reﬂected in diﬀerent cellularactions especially on cellular
phosphate transport.
2.Phosphate Transportinto Cells:
ContrastingEffectsofET-1and AngII
CAC in chronic kidney disease (CKD) has been strongly
linked to the hyperphosphatemia in severe CKD [17–20].
Predictors of CAC are higher serum phosphorus levels,lower
eGFR levels, and traditional CVD risk factors [21]. Each
1-mg/dl increase in serum phosphorus increases the odds
r a t i o sf o rC A Cb y1 . 5( p r e v a l e n c e )o r1 . 6( i n c i d e n c e )[ 21].
The reduction in CAC found in some dialysis patients who
received renal transplantation correlated with a decrease in
calcium x phosphate product, in the early period after renal
transplantation [22]. These data support the contention that
increased phosphate transport into VSMC may initiate the
process of vascular calciﬁcation.
Cellular phosphate transport exhibits saturable uptake
(Figure 1). VSMC express both high aﬃnity Na-dependent
and Na-independent components of Pi transport with sim-
ilar kinetic behavior [23]. The Na-coupled saturable uptake
has been explained by the expression of two type III sodium-
dependent phosphate cotransporter proteins, Pit1 and Pit2
[23]. Phosphate uptake into the aorta through Pit-1 can lead
to VSMC calciﬁcation by induction of apoptosis [13]o rb y
phosphate-induced phenotypic changes in VSMC to a cell
with the capacity to produce calciﬁcation [24]. The inﬂux
of phosphate through capillary membranes is mediated
by a saturable high-aﬃnity system which is independent
of sodium [25], but presumably, it is cellular phosphate
concentration rather than the transporter that regulates
cellular calciﬁcation.
Ang II produces a concentration-dependent reduction
in cellular phosphate transport (Figure 2)[ 26]. In some
tissues such as isolated bovine capillaries, however, Ang II
10 7.5 5 2.5 0
Pi concentration (mM)
0
25
50
75
R
a
t
e
o
f
P
i
u
p
t
a
k
e
(
n
m
o
l
/
m
g
p
r
o
t
e
i
n
/
m
i
n
)
Figure 1: Uptake of phosphate in the presence of various concen-
trations of phosphate (Pi). The data are the mean + SEM. The data
are adapted from Sunga and Rabkin [26].
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Figure 2: Inhibition of phosphate uptake in response to various
concentrations of Ang II. The inset shows the eﬀect of Ang
II (10−7 M) on phosphate uptake in the presence of various
extracellular phosphate concentrations. The data are adapted from
Sunga and Rabkin [26].
does not aﬀect phosphate transport [27] suggesting that
the eﬀect of Ang II impacts the type III sodium-dependent
phosphatecotransporter. IncontrasttoAngII,ET-1hasbeen
consistently demonstrated to increase cellular phosphate
transport. This has been demonstrated in capillaries [27],
brush border membrane vesicles [28] and mouse calvaria-
derived osteoblast-like MC3T3-E1 cells [29]. In MC3T3-
E1 osteoblast-like cells, ET-1 stimulates sodium-dependent
phosphate transport [29]. This eﬀect is medicated through
ET(A) and not ET(B) receptors [29]. ET1-induced stimula-
tion of Pi transport is mediated by PKC activation through
both phosphoinositide and phosphatidylcholine hydrolyses
[29]. Considering the kinetics of phosphate transport, ET-
1p r o d u c e sa4 2t o7 3 %i n c r e a s ei nVmax, depending on
tissue or cell type, in contrast to the 38% reduction in Vmax
observed in response to Ang II (Figure 3)[ 26, 28–30].International Journal of Nephrology 3
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Figure 3: The eﬀect of endothelin I (ET-1) and angiotensin II (Ang
II) on the kinetics of phosphate uptake Vmax in various studies.
3.EffectofET-1onVascularCalciﬁcation
ET-1 may induce vascular calciﬁcation through its potential
to induce VSMC apoptosis [31, 32]. VSMC apoptosis that
occurs with increased arterial loading is further accentuated
in the presence of ET-1 [31, 32]. Increases in arterial loading
conditions increase endothelial prepro-ET-1 and VSMC
endothelin B receptor expression [32] suggesting that the
eﬀectsofET-1 onthe vasculature can be induced from blood
pressure elevation regardless of its cause. The role of Ang II
to mediate cell apoptosis is less clear [33, 34].
Endothelin content and endothelin mRNA were in-
creasedinthemodelofvascularcalciﬁcationinwhich VSMC
are treated with beta-glycerophosphate [35]. In the in vivo
model of vascular calciﬁcation induced by vitamin D(3) plus
nicotine, endothelin levels in plasma and aorta as well as the
amount of endothelin mRNA in calciﬁed aorta are increased
[35]. The ET-1 antagonist bosentan signiﬁcantly reduced
vascular calciﬁcation in this model [35]. ET 1-A receptor
antagonists signiﬁcantly regress the vascular calciﬁcation
that is produced in the warfarin plus vitamin K model of
vascular calciﬁcation [36]. The ability of an ET-1 A receptor
antagonist to preventvascular calciﬁcation was much greater
than the angiotensin receptor blocker although both agents
reduced blood pressure [37]. These data strongly implicate
ET-1 in the pathogenesis of vascular calciﬁcation.
4.MatrixGlaProtein(MGP),Fetuin, and
Osteoprotegerin:ContrastingEffectsof
ET-1and Ang II
Matrix Gla protein (MGP) is a recognized inhibitor of
vascular calciﬁcation. Ang II increased MGP mRNAlevelsby
20% in neonatal rat cardiac myocytes and 40% in cardiac
ﬁbroblasts [38]. Increases in this inhibitor of calciﬁcation
would be expected to reduce vascular calciﬁcation. In con-
trast, ET-1 decreased MGP mRNA levels 30% in myocytes
and had no eﬀect in ﬁbroblasts [38]. Reductions in this
inhibitor of vascular calciﬁcation would be expected to
increase vascular calciﬁcation.
Osteoprotegerin (OPG) is an inhibitor of osteoclasto-
genesis and osteoclast activation. OPG inhibits advanced
atherosclerotic plaque progression by preventing an increase
in lesion size and lesion calciﬁcation [39]. In human aortic
smooth muscle cells, Ang II produces a dose-dependent
increase in the production of OPG [40]. A 3-fold increase
in suprarenal aortic concentration of OPG was observed
after chronic AngIIadministration inApoE(−/−)mice[40].
OPG secreted by explants of vascular tissue from human
endarterectomy samples was signiﬁcantly reduced within
48 hours of incubation with the Ang II receptor blocker
irbesartan [41].
Fetuin-A inhibits pathologic calciﬁcation in both soft
tissue and vasculature, even in the setting of atheroscle-
rosis [42]. Fetuin uptake and secretion by proliferating
and diﬀerentiating cells in the arterial wall is a protective
mechanism against arterial calciﬁcation [43]. Circulating
fetuin-A concentration decreases in parallel with decline
in renal function [44]. During predialysis stage of diabetic
nephropathy, there is a direct relationship between serum
fetuin-A levels and CAC score [45]. The combination of
fetuin-A deﬁciency, high-phosphate diet and CKD in ApoE-
deﬁcient mice greatly enhances calciﬁcation [42]. Thus
factors that increase phosphate transport into the cell would
be expected to enhance vascular calciﬁcation in the presence
of low fetuin-A levels. ET-1 levels increase with declining
renal function. Multiple regression analysis showed that
fetuin-A was signiﬁcantly inversely associated with ET-1 and
the relationship was independent of estimated glomerular
ﬁltration rate, sex, parathyroid hormone, and the calcium
x phosphorus product [44]. The negative correlation of
coronary artery calciﬁcation scores with serum fetuin-A
levels [46] coupled with the inverse relationship between
fetuin-A and ET-1 suggests that fetuin and ET-1 have
opposite actions leading to CAC. This possibility requires
further investigation.
5.CellularPromotersofCalciﬁcationBMP-2
and Osteopontin:Effectsof ET-1and Ang II
Although the role of bone morphogenic protein (BMP-2) in
vascular calciﬁcation is still being elucidated, there are data
that BMP-2 induces osteoblastic diﬀerentiation of VSMC
through induction of MSX-2 or by inducing apoptosis of
VSMC [47]. BMP-2 eﬀects may be related to the loss of
regulation of the matrix Gla protein [47]. In addition, BMP-
2 induces Runx2 and inhibits SM22 expression, indicating
that it promotes osteogenic phenotype transition in these
cells [48]. The action of BMP-2 can be related back to
an eﬀect on phosphate transport. BMP-2 upregulates Pit-
1 mRNA and protein levels [48]. Inhibition of phosphate
uptake abrogated BMP-2-induced calciﬁcation suggesting
that phosphate transport via Pit-1 is crucial in BMP-2
regulation of VSMC [48]. In the mouse osteoblast-like cell
line MC3T3-E1, ET-1 signiﬁcantly increased intracellular
Ca2+ concentration, DNA synthesis, and cell number [49].4 International Journal of Nephrology
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Figure 4: A simpliﬁed schematic of some of the putative eﬀects of endothelin-1 (ET-1) leading to vascular calciﬁcation discussed in this
paper.
The ability of ET-1 to induce mitosis and mitogen-activated
protein kinase phosphorylation in VSMC were signiﬁcantly
increased in the presence of BMP-2 [50]. In vivo studies
showed that tissue calcium content was signiﬁcantly higher
in the group that received both BMP-2 and ET-1 than in
the group receiving BMP-2 alone [49]. The eﬀect of ET-1 on
bone formation is operative through ET(A) receptors [49].
Osteopontin (OPN), a low-aﬃnity, high-capacity cal-
cium-binding phosphoproteins, colocalizes with dystrophic
arterial calciﬁcation. In human coronary artery segments,
obtained at autopsy, there were high amounts of OPN in the
outer margins of all diseased segments at each calciﬁcation
front [51]. ET-1 consistently induces OPN in a number of
diﬀerent cell types [52–55]. ET-1 enhances OPN as well as
various other factors that induce bone formation such as
osteocalcin and bone sialoprotein [52]. ET-1 enhanced by
approximately twofold the mRNA expression of both osteo-
pontin and osteocalcin genes in rat osteoblastic osteosar-
coma ROS17/2.8 cells [55]. ET-1 modulation of the expres-
sion of these two gene products of osteoblasts suggests that
ET-1 plays a role in the regulation of bone metabolism [55].
Ang II produces similar eﬀects on OPN as ET-1. Ang II
also induces OPN expression in VSMC [56, 57]. The eﬀect
of AngII on OPN is mediated by signaling cascades involving
G(q/11),theRas-ERKaxis,p42/44MAPK,andtheSrckinase
family and by the transcription factor, Ets-1 [57, 58].
6.EffectofET-1and Ang II onBone Formation
The process of vascular calciﬁcation is analogous to bone
formation. The putative eﬀects of Ang II and ET-1 on
vascularcalciﬁcationare consistentwith theireﬀectsonbone
formation. ET-1 promotes both osteoblastic proliferation
and diﬀerentiation leading to the formation of bone nodules
in osteoblastic progenitor cells [59]. ET-1 modulation of the
expression of the two phenotype-related gene products of
osteoblasts suggests that ET-1 modulates osteoblastic func-
tions and plays a role in the regulation of bone metabolism
[55]. There is some contrary data. ET may decrease the
expression of mRNA for osteocalcin, which is a marker
protein for the maturation of osteoblastic cells and inhibit
the mineralization of osteoblastic cells in vitro under some
circumstances [60].
The eﬀect of Ang II is diﬀerent from ET-1. Ang II
decreased alkaline phosphatase activity in bone cell popu-
lations derived from the periosteum of fetal rat calvariae
consistent with reduction in bone formation [61]. Ang II
also stimulates bone resorption. This has been demonstrated
in both in vitro and in vivo models. Ang II stimulated
bone resorption in cocultures ofosteoclasts with osteoblastic
cells [62]. In bone marrow-derived mononuclear cells, Ang
II signiﬁcantly increased osteoclasts via RANKL induction
[63]. In a rat ovariectomy model of estrogen deﬁciency,
administration of Ang II accelerated the decrease in bone
density and Ang II receptor antagonism attenuated the
decrease in bone density [63]. These data strongly point to
a role for Ang II as factor that reduces the amount of bone
mineralization.
7.Conclusion
In summary, the link between hypertension and coronary
artery calciﬁcation can be related to an action of the
vasoconstrictor peptide ET-1 on several processes that have
been implicated in the pathogenesis of coronary artery
calciﬁcation. This is illustrated in Figure 4. The ability of
ET1 to consistently increase phosphate transport into the
cell suggests that in conditions of hyperphosphatemia, that
may occurs in end-stage chronic kidney disease, there is a
heightened entry of phosphate into vascular smooth muscle.
An increase in cellular phosphate can increase cellular
calciﬁcation through at least three diﬀerent mechanisms—
an increase in calcium x phosphate product transformation
of VSMC to a bone-producing cell phenotype or cell apop-
tosis that releases procalciﬁc substances. ET-1 aﬀects other
modulators of calciﬁcation in a manner that tips the balance
in favor of calciﬁcation, namely, inhibiting the inhibitors of
calciﬁcation, matrix Gla as well as osteoprotegerin and per-
haps fetuin while enhancing the eﬀects of procalciﬁc factors
such as BMP-2 and osteopontin. In contrast, another vaso-
constrictor peptide operative in hypertension, angiotensin
II, is highly unlikely to be responsible for coronary arteryInternational Journal of Nephrology 5
calciﬁcation. Ang II inhibits cellular phosphate transport,
and increases the presence of inhibitors of calciﬁcation,
matrix Gla protein and osteoprotegerin.
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